A Study of RO4917523 in Patients With Fragile X Syndrome

Summary

This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4917523 in adolescent and adult patients with fragile X syndrome. Patients will be randomized to receive oral doses of 0.5 mg or 1.5 mg of RO4917523, or matching placebo once daily. The anticipated time on study treatment is 12 weeks.

Timeline

Start

2012-05

Primary completion

2014-04

Completion

2014-04

Drugs

Indications